314 related articles for article (PubMed ID: 33632232)
1. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
Gote V; Sharma AD; Pal D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
[TBL] [Abstract][Full Text] [Related]
4. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer.
Sharma R; Yadav V; Jha S; Dighe S; Jain S
Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
9. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
10. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
11. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation.
Duan T; Xu Z; Sun F; Wang Y; Zhang J; Luo C; Wang M
Biomed Pharmacother; 2019 Sep; 117():109121. PubMed ID: 31252265
[TBL] [Abstract][Full Text] [Related]
12. Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer.
Guo XM; Yadav MB; Khan M; Hao CW; Lin CY; Huang T; Wu J; Fan BM; Bian ZX
J Med Chem; 2021 Dec; 64(23):17051-17062. PubMed ID: 34699215
[TBL] [Abstract][Full Text] [Related]
13. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
15. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
16. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
17. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
18. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
19. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
20. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
Kuryk L; Mathlouthi S; Wieczorek M; Gad B; Rinner B; Malfanti A; Mastrotto F; Salmaso S; Caliceti P; Garofalo M
Eur J Pharm Biopharm; 2024 Jun; 199():114300. PubMed ID: 38697488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
